The DOI matches its Crossref record.
Circulating FGF-21 Levels in Normal Subjects and in Newly Diagnose Patients with Type 2 Diabetes Mellitus
Abstract
Fibroplast growth factor (FGF-21) is a recently discovered metabolic regulator. Its pathophysiologic role in humans remains unknown. In this study, we have investigated whether or not plasma FGF-21 level was different in patients with type 2 diabetes mellitus (T2DM) and non-diabetic controls. We also assessed associations between plasma FGF-21 body composition and several metabolic parameters. Fasting FGF-21 levels were significantly increased in patients with T2DM compared with controls (1.82+/-0.65 VS. 1.53+/-0.60 microg/L, P<0.05). In T2DM patients, fasting plasma FGF-21 correlate negatively with fasting blood glucose ( R= -0.31, P<0.05). Multiple regression analysis showed that FBG, plasma insulin and HOMA (IS) were independent influencing plasma FGF-21 levels. The present work suggests a potential role for FGF-21 in the pathogenesis of insulin resistance and T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Circulating levels of FGF21 are significantly elevated in humans during pathophysiological states, including type 2 diabetes (16, 18), obesity (22, 30, 93), hepatosteatosis (30, 79, 146), pancreatitis (117, 137), and mitochondrial dysfunction (78).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [18]
Citations
Cited by
Sorted by citations
Items 101–186 of 186
Lindegaard, B., Hvid, T., Grøndahl, T. S., Frøsig, C., Gerstoft, J., Højman, P., & Pedersen, B. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055632 · Cited by 32
Wang, C., Dai, J., Yang, M., Deng, G., Xu, S., Jia, Y., Boden, G. H., Ma, Z. A., Yang, G., & Li, L. (2014) · FEBS Journal · doi:10.1111/febs.12767 · Cited by 32
Self-citationPost, A., Dam, W., Sokooti, S., Groothof, D., Gloerich, J., van Gool, A. J., Kremer, D., Gansevoort, R. T., van den Born, J., Kema, I. P., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac729 · Cited by 30
FGF21 as a Therapeutic Reagent
Zhao, Y., Dunbar, J. D., & Kharitonenkov, A. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0887-1_14 · Cited by 30
Yang, M., Dong, J., Liu, H., Li, L., & Yang, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026359 · Cited by 30
Self-citationEvaluation of concentrations of FGF-21 - a new adipocytokine in type 2 diabetes.
Matuszek, B., Lenart-Lipińska, M., Duma, D., Solski, J., & Nowakowski, A. M. (2010) · PubMed · Cited by 30
Whytock, K. L., Carnero, E. A., Vega, R. B., Tillner, J., Bock, C., Chivukula, K., Yi, F., Meyer, C., Smith, S. R., & Sparks, L. M. (2021) · Obesity · doi:10.1002/oby.23141 · Cited by 30
Fjeldborg, K., Pedersen, S. B., Møller, H. J., & Richelsen, B. (2017) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2017.03.033 · Cited by 28
Fibroblast Growth Factor 21: A Novel Metabolic Regulator
Seo, J. A., & Kim, N. H. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.1.26 · Cited by 27
Liu, W., Huang, S., Shi, K., Zhao, C., Chen, L.-L., Braddock, M., Chen, Y., Feng, W., & Zheng, M. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.944898 · Cited by 26
Relationship of Selected Adipokines with Markers of Vascular Damage in Patients with Type 2 Diabetes
Spurná, J., Karásek, D., Kučerová, V., Goldmannová, D., Krystyník, O., Schovánek, J., & Zadražil, J. (2018) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2017.0179 · Cited by 26
Strączkowski, M., Karczewska‐Kupczewska, M., Adamska, A., Otziomek, E., Kowalska, I., & Nikołajuk, A. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.10 · Cited by 25
Pérez‐Martí, A., Sandoval, V., Marrero, P. F., Haro, D., & Relat, J. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0034 · Cited by 24
Wang, N., Xu, T.-Y., Zhang, X., Li, J.-Y., Wang, Y.-X., Guo, X.-C., Li, S.-M., Wang, W.-F., & Li, D.-S. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.01.048 · Cited by 23
Collino, M., Benetti, E., Rogazzo, M., Chiazza, F., Mastrocola, R., Nigro, D., Cutrìn, J. C., Aragno, M., Fantozzi, R., Minetto, M. A., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12888 · Cited by 23
RetractedSerum FGF21 and RBP4 levels in patients with chronic hepatitis C
Kukla, M., Berdowska, A., Stygar, D. M., Gabriel, A., Mazur, W., Łogiewa-Bazger, B., Sobala‐Szczygieł, B., Bułdak, R. J., Rokitka, M., Zajęcki, W., et al. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.694901 · Cited by 23
Gallego-Escuredo, J. M., Domingo, P., Gutiérrez, M. D. M., Mateo, G. M., Cabeza, M. C., Fontanet, À., Vidal, F., Domingo, J. C., Giralt, M., & Villarroya, F. (2012) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318271c2c7 · Cited by 22
Salehi, M. H., Kamalıdehghan, B., Houshmand, M., Aryani, O., Sadeghizadeh, M., & Mossalaeie, M. M. (2013) · Molecular Biology Reports · doi:10.1007/s11033-013-2767-0 · Cited by 23
Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus
Guo, C. Y., Zhao, L., Li, Y., Deng, X., & Yuan, G. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29879 · Cited by 21
Şahin, S. B., Ayaz, T., Cüre, M. C., Sezgin, H., Ural, Ü. M., Balık, G., & Şahin, F. K. (2014) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2014.900821 · Cited by 21
Zhang, M., Zeng, L., Wang, Y.-J., An, Z., & Ying, B.-W. (2012) · DNA and Cell Biology · doi:10.1089/dna.2011.1302 · Cited by 21
Lee, S. A., Jeong, E., Kim, E. H., Shin, M., Hwang, J. Y., Koh, E. H., Lee, W. J., Park, J., & Kim, M. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.1.29 · Cited by 19
Current understanding and controversies on the clinical implications of fibroblast growth factor 21
Badakhshi, Y., & Jin, T. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2020.1864278 · Cited by 20
Zibar, K., Blaslov, K., Bulum, T., Čuča, J. K., & Duvnjak, L. S. (2014) · Endocrine · doi:10.1007/s12020-014-0413-9 · Cited by 19
Akyıldız, Z. İ., Polat, S., Yürekli, B. Ş., Kocabaş, G. Ü., Tülüce, K., Tülüce, S. Y., Kocabaş, U., Bozkaya, G., Yüksel, A., & Nazlı, C. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0185-3 · Cited by 19
Lazo-de-la-Vega-Monroy, M.-L., Solı́s-Martı́nez, M. O., Romero‐Gutiérrez, G., Aguirre-Arzola, V. E., Wróbel, K., Wróbel, K., Zaina, S., & Barbosa‐Sabanero, G. (2017) · Steroids · doi:10.1016/j.steroids.2017.05.007 · Cited by 19
Glycerol-3-phosphate activates ChREBP, FGF21 transcription and lipogenesis in citrin deficiency
Tiwari, V., Jin, B., Sun, O., Gonzalez, E. D. J. L., Chen, M.-H., Wu, X., Shah, H., Zhang, A., Herman, M. A., Spracklen, C. N., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01399-3 · Cited by 20
Fan, H. J., Sun, X., Zhang, H., Liu, J., Zhang, P., Xu, Y., Pan, Q., & Wang, G. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0261 · Cited by 18
Zhang, M., Liu, Y., Xiong, Z.-Y., Deng, Z., Song, H., & An, Z. (2013) · PubMed · Cited by 17
Zarei, M., Pujol, E., Quesada‐López, T., Villarroya, F., Barroso, E., Vázquez, S., Pizarro‐Delgado, J., Palomer, X., & Vázquez‐Carrera, M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14678 · Cited by 17
Tehrani, A. N., Hatami, B., Helli, B., Yari, Z., Daftari, G., Salehpour, A., Hedayati, M., Khalili, E., Hosseini, S. A., & Hekmatdoost, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-55747-6 · Cited by 16
Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms
Richter, M. M., Kemp, I. M., Heebøll, S., Winther‐Sørensen, M., Kjeldsen, S. A. S., Jensen, N. J., Nybing, J. D., Linden, F. H., Høgh‐Schmidt, E., Boesen, M., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155915 · Cited by 15
Jung, C., Jung, S.-H., Kim, B., Kim, C., Kang, S., & Mok, J. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.017 · Cited by 15
Predictors of weight loss in patients with obesity treated with a Very Low-Calorie Ketogenic Diet
Ernesti, I., Baratta, F., Watanabe, M., Risi, R., Camajani, E., Persichetti, A., Tuccinardi, D., Mariani, S., Lubrano, C., Genco, A., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1058364 · Cited by 19
KLOTHO, FGF21 AND FGF23: NOVEL PATHWAYS TO MUSCULOSKELETAL HEALTH?
Bartali, B., Semba, R. D., & de Araújo, A. B. (2013) · The Journal of Frailty & Aging · doi:10.14283/jfa.2013.26 · Cited by 12
Sun, M., Jin, L., Bai, Y., Wang, L., Zhao, S., Ma, C., & Ma, D. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29260 · Cited by 13
Biomarker Qualification via Public–Private Partnerships
Eck, S. L., & Paul, S. M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.193 · Cited by 13
Sutton, E. F., Morrison, C. D., Stephens, J. M., & Redman, L. M. (2018) · Endocrine Research · doi:10.1080/07435800.2018.1473421 · Cited by 13
White adipose tissue in type 2 diabetes and the effect of antidiabetic drugs
Zhao, Y., & Yue, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01678-9 · Cited by 13
Sun, X., Li, M., Li, A., Lan, X., Lei, C., Ma, W., Hua, L.-S., Wang, J., Hu, S., & Chen, H. (2013) · Livestock Science · doi:10.1016/j.livsci.2013.03.023 · Cited by 12
Richter, M. M., Thomsen, M. N., Skytte, M. J., Kjeldsen, S. A. S., Samkani, A., Frystyk, J., Magkos, F., Holst, J. J., Madsbad, S., Krarup, T., et al. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae008 · Cited by 13
Eissa, L. A., Abdel‐Rahman, N., & Eraky, S. M. (2015) · Egyptian Journal of Basic and Applied Sciences · doi:10.1016/j.ejbas.2015.01.002 · Cited by 11
Karamfilova, V., Assyov, Y. S., Nedeva, I., Gateva, A., Ivanova, I. D., Cherkezov, N., Mateva, L., & Kamenov, Z. A. (2021) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2021.201165 · Cited by 10
Samms, R. J., Cheng, C., Fourcaudot, M. J., Heikkinen, S., Khattab, A., Adams, J. M., Cersósimo, E., Triplitt, C. L., PUCKETT, C. L., Tsintzas, K., et al. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00050.2022 · Cited by 10
FGF21 Is Associated with Acanthosis Nigricans in Obese Patients
Huang, Y., Yang, J., Li, Y., Chen, J., Song, K., Wang, X., Bu, L., Cheng, X., Wang, J., & Qu, S. (2016) · International Journal of Endocrinology · doi:10.1155/2016/1658062 · Cited by 10
The Role of the FGF19 Family in the Pathogenesis of Gestational Diabetes: A Narrative Review
Sadowska, A., Poniedziałek‐Czajkowska, E., & Mierzyński, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417298 · Cited by 9
Fibroblast Growth Factor 21 Mimetics for Treating Atherosclerosis
Kwok, K. H. M., & Lam, K. S. L. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.2.145 · Cited by 9
Xu, C., Han, Z., Li, P., & Li, X. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6291 · Cited by 9
Heidari, Z., & Hasanpour, M. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.102296 · Cited by 9
The Diagnostic Role of FGF 21 in Endometrial Cancer and Other Pathologies of the Uterine Corpus
Jagodzińska, A., Chudecka-Glaz, A. M., Michalczyk, K., Pius‐Sadowska, E., Wieder-Huszla, S., Jurczak, A., & Machaliński, B. (2023) · Diagnostics · doi:10.3390/diagnostics13030399 · Cited by 9
Fibroblast Growth Factor 21 Is Elevated in HIV and Associated With Interleukin-6
Eckard, A. R., Hughes, H., Hagood, N. L., O’Riordan, M. A., Labbato, D. E., Kosco, J. C., Scott, S., & McComsey, G. A. (2020) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002285 · Cited by 8
Payne, B. A. I., Price, D., & Chinnery, P. F. (2013) · AIDS Research and Therapy · doi:10.1186/1742-6405-10-27 · Cited by 8
Fibroblast growth factor 21 – a key player in cardiovascular disorders?
Lenart-Lipińska, M., Duma, D., Hałabiś, M., Dziedzic, M., & Solski, J. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0026 · Cited by 8
Mashili, F. L., Ramaiya, K. L., Lutale, J. K., Njelekela, M. A., Francis, F. T., Zierath, J. R., & Krook, A. (2018) · Journal of Obesity · doi:10.1155/2018/7461903 · Cited by 8
Fernandes, M. J., Hechtman, P., Boulay, B., & Kaplan, F. (1997) · European Journal of Human Genetics · doi:10.1159/000484748 · Cited by 8
Biochemical Interaction Between Muscle and Bone: A Physiological Reality?
Jaspers, R. T., & Bravenboer, N. (2014) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-014-9156-7 · Cited by 7
The Regulation of Circulating Hepatokines by Fructose Ingestion in Humans
Richter, M. M., & Plomgaard, P. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab121 · Cited by 7
Wang, N., Sun, B., Guo, H., Jing, Y., Qi, R., Wang, M., Mi, Y., Chen, H., Song, L., & Cui, W. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.795520 · Cited by 6
Olivares, S., & Henkel, A. S. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.09.006 · Cited by 6
Insights into the role of FGF21 in coronary heart disease
Zhang, Q.-Y., & Liu, H. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136911 · Cited by 4
Self-citationUittenbogaard, M. N., & Chiaramello, A. (2015) · PubMed · Cited by 4
Shafaei, A., Khoshnia, M., & Marjani, A. (2015) · Journal of Medical Sciences(Faisalabad) · doi:10.3923/jms.2015.80.86 · Cited by 4
Fournier, C., Karagounis, L. G., Sacco, S. M., Horcajada, M.-N., Decaens, T., Offord, E., Bouzakri, K., & Ammann, P. (2022) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2022.108952 · Cited by 3
You, L., Hong, X., Wu, H., Liang, D., Li, F., Zheng, D., Zhang, X., Liu, D., Chen, Q., Yan, L., et al. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01426-y · Cited by 4
Matta, R., El-Hini, S. H., Saad, M., Mostafa, H., & AbedelfadeeL, A. (2017) · Egyptian Journal of Obesity Diabetes and Endocrinology · doi:10.4103/ejode.ejode_30_16 · Cited by 3
Serum FGF-21 Levels During COVID-19 Infection Recovery Period
Demir, A. D., Cetin, Z., & Sezgin, F. M. (2024) · Medical Bulletin of Haseki · doi:10.4274/haseki.galenos.2024.9752 · Cited by 2
The FGF Family in Humans, Mice, and Zebrafish: Development, Physiology, and Pathophysiology
Sasaki, S., Ohta, H., Nakajima, Y., Konishi, M., Miyake, A., & Itoh, N. (2011) · InTech eBooks · doi:10.5772/22859 · Cited by 4
Fibroblast growth factor-21: A link for glucose homeostasis
Naderali, E. K., Wong, C., & Hussain, M. (2009) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2009.07.002 · Cited by 2
Fibroblast growth factor 21: new insights from human studies
Hansen, J. S., & Plomgaard, P. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000084 · Cited by 2
Fibroblast Growth Factor 21 as a Novel Metabolic Regulator
Micanovic, R., Dunbar, J. D., & Kharitonenkov, A. (2011) · Wiley eBooks · doi:10.1002/9780470910016.ch14 · Cited by 2
Adipose tissue biomarkers and systemic health
Ștefani, C., Miricescu, D., Totan, A., Greabu, M., & Stănescu, A. M. A. (2019) · Romanian Journal of Medical Practice · doi:10.37897/rjmp.2019.4.3 · Cited by 1
Fibroblast Growth Factor Receptor-2 Involved in FGF-21-mediated Glucose Metabolism*
Ren, G., Li, L., Sun, G., et al. (2009) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/sp.j.1206.2008.00323 · Cited by 1
Self-citationLY2405310 : un analogue du FGF21 avec une efficacité métabolique partielle
Dubois‐Laforgue, D. (2014) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(14)70753-9
Changes in Cardiotrophin-1 and Fibroblast Growth Factor-21 with Weight Loss
Bowers, R. L. (2009)
Dushay, J. R., Chui, P. C., Gopalakrishnan, G. S., Crawley, M. B., Fisher, F. M., & Badman, M. K. (2010)
Molecular Regulators of Metabolism and Cardiometabolic Disease
Sukmawati, I. R., & Wijaya, A. (2012) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v4i3.173
Ding, L., Hao, Z., Yuan, Q., Xu, P., Yu, Y.-H., & Li, D. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3753
Fibroblast Growth Factor 21 Association with Renal Function Decline in Type II Diabetes Mellitus
Zainab A. Hussein 1, S. A. A. 2. (2020) · Indian Journal of Forensic Medicine & Toxicology · doi:10.37506/ijfmt.v14i4.12000
Current literature in diabetes
(2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.914
Jin, Q., Bando, Y., Miyawaki, K., Shikama, Y., Kosugi, C., Aki, N., Funaki, M., & Noji, S. (2000) · The Journal of Medical Investigation · doi:10.2152/jmi.40.28
Cross-talk between hepatokines as Liver indused-exercise factors and organokinesPreprint
Rad, R. S. (2023) · Research Square · doi:10.21203/rs.3.rs-3734627/v1
Signaling pathway and pharmacology
Li, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15793-6.00005-6
Murugiah, V., Pal, P., Sahoo, J. P., et al. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1804_24
Escuredo, G., & Miguel, J. (2012) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Étude du rôle de la production hépatique de glucose dans le développement du diabète et de l’obésité
Abdul-Wahed, A. (2012) · theses.fr (ABES) · doi:10.70675/61924053za287z4f04zb650zc51c1916ee64
Metadata
- Authors
- Chen, W.-W., Li, L., Yang, G.-Y., Li, K., Qi, X.-Y., Zhu, W., Tang, Y., Liu, H., & Boden, G.
- Affiliations
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Venue
- Experimental and Clinical Endocrinology & Diabetes
- Publisher
- Georg Thieme Verlag KG
- Published
- 2007-10-09
- Volume
- 116
- Issue
- 01
- Pages
- 65-68
- ISSN
- 0947-7349 (ISSN-L)
- 1439-3646
- OpenAlex
- W2031514101
- Cited by
- 186
- References
- 0
- Citations by year
- 2025: 3 · 2024: 6 · 2023: 5 · 2022: 6 · 2021: 5 · 2020: 8 · 2019: 7 · 2018: 7 · 2017: 14 · 2016: 13 · 2015: 6 · 2014: 14 · 2013: 19 · 2012: 21
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Experimental and Clinical Endocrinology & Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01-HL-0733267)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 066003, R01DK066003)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › GDF15 and Related Biomarkers
- Keywords
- FGF21, type 2 diabetes, fasting blood glucose, insulin resistance, HOMA-IR, insulin, body composition, metabolic regulation
- MeSH terms
- Adult, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Fasting, Female, Fibroblast Growth Factors, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Male, Middle Aged, Regression Analysis, Triglycerides, Waist-Hip Ratio
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
